QoL evaluation of olanzapine for chemotherapy‐induced nausea and vomiting comparing with 5‐ HT 3 receptor antagonist

This study evaluated the efficacy of olanzapine in preventing chemotherapy‐induced nausea and vomiting ( CINV ) and improving the quality of life ( QoL ) of patients with cancer during chemotherapy. Two hundred twenty‐nine patients with cancer who received chemotherapy from J anuary 2008 to A ugust 2008 were enrolled, and they were randomised to receive olanzapine or a 5‐ HT 3 receptor antagonist. The patients completed a CINV questionnaire once daily on days 1–5 and a QoL questionnaire on days 0 and 6. The complete response ( CR ) rates for nausea (76.85% versus 46.2%) and vomiting (84.3% versus 67.6%) were significantly higher in the olanzapine group than in the 5‐ HT 3 receptor antagonist group for delayed CINV but not for acute CINV . The CR rates for nausea (76.85% versus 44.44%) and vomiting (85.95% versus 67.59%) were also significantly higher in the olanzapine group for the 5 days post‐chemotherapy. After chemotherapy, global health status, emotional functioning, and insomnia were improved in the olanzapine group but worsened in the 5‐ HT 3 receptor antagonist group, whereas cognitive functioning and appetite loss were unchanged. Moreover, olanzapine significantly improved global health status, emotional functioning, social functioning, fatigue, nausea/vomiting, insomnia, and appetite loss. Olanzapine improved the QoL of patients with cancer during chemotherapy, in part by reducing the incidence of delayed CINV .